首页> 美国卫生研究院文献>British Journal of Clinical Pharmacology >Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size
【2h】

Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size

机译:吸入单分散倍氯米松的药代动力学与粒径的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>What is already known about this subject class="unordered" style="list-style-type:disc">For asthmatic adults, bronchodilators with a MMAD between 3 and 6 µm were shown to give the best improvement in lung function and the least systemic side-effects.It is not known, however, what is the most efficacious particle size for inhaled steroids in asthmatic adults. Clinical efficacy and systemic side-effects of inhaled steroids should be measured to define the optimal particle size.>What this study adds class="unordered" style="list-style-type:disc">Our study investigated the systemic absorption of inhaled steroids. We found that a particle size of 2.5 µm and 4.5 µm gave a higher pulmonary bioavailability compared with the 1.5 µm monodisperse aerosols in adults with mild asthma and therefore were more likely to elicit systemic adverse effects.AimsFor optimal efficacy, antiasthma drugs should be delivered to the desired region in the airways. To date, the optimal particle size for steroids in adults is not known. The aim of the study was to evaluate the pulmonary bioavailability for inhaled beclomethasone dipropionate (BDP) aerosols of different particle sizes.
机译:>关于此主题的已知信息 class =“ unordered” style =“ list-style-type:disc”> <!-list-behavior = unordered prefix-word = mark-type = disc max-label-size = 0-> 对于哮喘成年人,MMAD在3至6 µm之间的支气管扩张剂显示出肺功能的最佳改善和最小的全身性副作用。 < li>但是,尚不清楚哮喘成年人中吸入类固醇的最有效粒径是多少。应该测量吸入类固醇的临床疗效和全身副作用,以定义最佳粒径。 >这项研究添加的内容 class =“ unordered” style =“ list -style-type:disc“> <!-list-behavior =无序前缀-word = mark-type = disc max-label-size = 0-> 我们的研究调查了吸入类固醇的全身吸收。我们发现,在轻度哮喘患者中,与1.5 µm单分散气雾剂相比,粒径分别为2.5 µm和4.5 µm的肺具有更高的肺生物利用度,因此更可能引起全身性不良反应。 目标疗效方面,抗哮喘药物应递送至气道的所需区域。迄今为止,成人中类固醇的最佳粒径尚不清楚。该研究的目的是评估吸入的不同粒径倍氯米松双丙酸酯(BDP)气雾剂的肺生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号